AbbVie Earnings Beat Expectations As Immunology And Neuroscience Drive Growth

Core Insights - AbbVie Inc. reported fourth-quarter earnings and revenue that surpassed Wall Street expectations, driven by strong performance in its immunology and neuroscience segments, although shares fell over 2% in premarket trading after the announcement [1] Financial Performance - The company posted adjusted earnings per share of $2.71 for the quarter, exceeding the consensus estimate of $2.65 [2] - Revenue reached $16.62 billion, surpassing analyst expectations of $16.39 billion, reflecting a year-over-year growth of 10.0%, or 9.5% on an operational basis [2] Segment Performance - Immunology was the main growth driver, with global net revenues increasing by 18.3% to $8.63 billion [3] - Skyrizi generated $5.01 billion in sales, marking a 32.5% increase from the previous year, while Rinvoq contributed $2.37 billion, representing a growth of 29.5% [3] - Sales of Humira declined by 25.9% to $1.25 billion due to biosimilar competition, but the gains in Skyrizi and Rinvoq offset this decline [3] - The neuroscience portfolio also performed well, with revenue rising 17.9% to $2.96 billion [4] - Vraylar sales increased by 10.5% to $1.02 billion, and Botox Therapeutic revenue advanced by 13.4% to $990 million [4] - The oncology portfolio saw a slight decline of 1.5% to $1.66 billion, primarily due to a 20.8% drop in Imbruvica sales, although growth in Venclexta and Elahere partially offset this [4] Future Guidance - AbbVie provided full-year 2026 adjusted earnings guidance of $14.37 to $14.57 per share, which is above the analyst consensus of $14.22 [5]